2011 Annual Meeting | Differential Diagnosis of Dementia: Linking Clinical Syndromes to Biomarkers

Date Saturday 04/09/11

Time 09:00 AM - 11:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) John C. Morris, MD, FAAN

Topic(s)

Learning Objectives Participants should understand the basis for the clinical diagnoses of Alzheimer's disease in relation to dementing disorders that often mimic its presentation and also will understand the potential clinical utlility of biofluid and imaging biomarkers for Alzheimer's disease.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
09:00 AM - 09:05 AM		Welcome John C. Morris, MD, FAAN
09:00 AM - 11:00 AM		Break
09:10 AM - 09:40 AM		Clinical Diagnosis of Alzheimer's Disease Jeffrey M. Burns, MD, John C. Morris, MD, FAAN
09:40 AM - 10:10 AM		Alzheimer Biomarkers and Revised Diagnostic Criteria Jeffrey M. Burns, MD, John C. Morris, MD, FAAN
10:10 AM - 10:30 AM		Alzheimer Mimics Jeffrey M. Burns, MD, John C. Morris, MD, FAAN
10:30 AM - 11:00 AM		Case Presentations Jeffrey M. Burns, MD, John C. Morris, MD, FAAN

Faculty Disclosures
John C. Morris, MD, FAAN	Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CBR International Advisory Board. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cure Alzheimers Fund. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LEADS Steering Commitee. The institution of Dr. Morris has received research support from NIH grants. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care.
Jeffrey M. Burns, MD	Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Renew Research. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Norris, Keplinger, Hicks and Welder. The institution of Dr. Burns has received research support from National Institutes of Health. The institution of Dr. Burns has received research support from Biogen. The institution of Dr. Burns has received research support from Eli Lilly. The institution of Dr. Burns has received research support from Amylyx. The institution of Dr. Burns has received research support from Abbvie. The institution of Dr. Burns has received research support from Astra-Zeneca.

��ɫ��

��ɫ��